A Study of AK130 in Patients With Advanced Malignant Tumors

Exclusion Criteria

• •1. Any malignancy other than the disease under study within the past 3 years except for radically cured local cancers, such as basal cell skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of breast.
• •2. Receipt of any anti-TIGIT, anti-TGF-β treatment.
• •3. Experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids.
• •5. Major surgical procedure within 4 weeks prior to the first dose of AK130 or still recovering from prior surgery.
• •6. History of organ transplant.
• •7. Known allergy or reaction to any component of the AK130 formulation. History of severe hypersensitivity reactions to other mAbs.